Rivoceranib
Rivoceranib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target proto-oncogene tyrosine-protein kinase receptor Ret, mast/stem cell growth factor receptor Kit, tyrosine-protein kinase CSK, and vascular endothelial growth factor receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
427 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 8 | 40 | 14 | 3 | 3 | 58 |
| Non-small-cell lung carcinoma | D002289 | 4 | 27 | 6 | 2 | 4 | 39 | ||
| Neoplasms | D009369 | C80 | 14 | 12 | 1 | 2 | 1 | 27 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 14 | 3 | 1 | 1 | 17 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 11 | 2 | 1 | — | 15 |
| Esophageal neoplasms | D004938 | C15 | — | 9 | 2 | 1 | 1 | 12 | |
| Hepatocellular carcinoma | D006528 | C22.0 | — | 5 | 2 | 1 | 2 | 10 | |
| Uterine cervical neoplasms | D002583 | — | 4 | — | 1 | 1 | 6 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | 1 | — | 1 | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 1 | — | 1 | — | 2 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 4 | 26 | 6 | — | 5 | 35 |
| Small cell lung carcinoma | D055752 | 1 | 11 | 3 | — | — | 14 | ||
| Triple negative breast neoplasms | D064726 | 3 | 9 | 2 | — | — | 13 | ||
| Adenocarcinoma | D000230 | 3 | 9 | 1 | — | 1 | 13 | ||
| Lung neoplasms | D008175 | C34.90 | 2 | 8 | 1 | — | 1 | 10 | |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 5 | 1 | — | — | 6 | |
| Immunotherapy | D007167 | — | 3 | 1 | — | 1 | 5 | ||
| Osteosarcoma | D012516 | — | 4 | 1 | — | — | 4 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 1 | — | — | 4 | |
| Gastrointestinal neoplasms | D005770 | C26.9 | — | 2 | 1 | — | — | 3 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 3 | 15 | — | — | 2 | 17 | ||
| Sarcoma | D012509 | 1 | 12 | — | — | — | 13 | ||
| Esophageal squamous cell carcinoma | D000077277 | 1 | 9 | — | — | — | 10 | ||
| Nasopharyngeal neoplasms | D009303 | — | 10 | — | — | — | 10 | ||
| Cholangiocarcinoma | D018281 | C22.1 | — | 7 | — | — | 1 | 8 | |
| Biliary tract neoplasms | D001661 | C24.9 | 1 | 7 | — | — | — | 7 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | 7 | — | — | — | 7 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 6 | — | — | — | 6 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | 2 | — | — | 2 | 4 | |
| Adenocarcinoma of lung | D000077192 | 1 | 3 | — | — | — | 4 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Urologic neoplasms | D014571 | C64-C68 | 1 | — | — | — | — | 1 | |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adjuvant chemotherapy | D017024 | — | — | — | — | 1 | 1 | ||
| Fatal outcome | D017809 | — | — | — | — | 1 | 1 | ||
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RIVOCERANIB |
| INN | rivoceranib |
| Description | Apatinib, also known as rivoceranib, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically, apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
|
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1984042-84-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3186534 |
| ChEBI ID | — |
| PubChem CID | 11315474 |
| DrugBank | DB14765 |
| UNII ID | 5S371K6132 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RET
RET
KIT
KIT
CSK
CSK
KDR
KDR
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 120 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more